A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A

Registry ID

EUCTR2012-001711-23

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novo Nordisk A/S

Start date

2012-12-05

Last update

2026-08-16

Conditions

• Haemophilia A

Summary

To evaluate immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP)

Locations

• , , Greece
• , , Italy
• , , UK
• , , Portugal
• , , Lithuania
• , , Germany

Related clinical trials

• Prevention of bleeding in haemophilia A by prophylactic treatment with Nuwiq®
• A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
• Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)
• A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
• Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

View on source registry